Open-Label Study of ZYN002 Administered as a Transdermal Gel to Children and Adolescents With 22q11.2 Deletion Syndrome
Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
To evaluate the safety and tolerability of ZYN002 administered as a transdermal gel
formulation, for up to 38 weeks, in patients ages 4 to < 18 years, in the treatment of
22q.11.2 Deletion Syndrome (22qDS).